LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

18.96 -2.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.72

Максимум

19.42

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+89.46% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-95M 2.1B
Предишно отваряне	21.18
Предишно затваряне	18.96

Настроения в новините

By Acuity

50%

147 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.03.2026 г., 19:18 ч. UTC

Значими двигатели на пазара

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11.03.2026 г., 23:54 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

11.03.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11.03.2026 г., 23:51 ч. UTC

Пазарно говорене

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11.03.2026 г., 23:41 ч. UTC

Пазарно говорене

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11.03.2026 г., 22:29 ч. UTC

Пазарно говорене

Australia Shares Set to Fall in Early Trade -- Market Talk

11.03.2026 г., 21:47 ч. UTC

Печалби

Liontown Resources: Market Tailwinds Strengthening Outlook

11.03.2026 г., 21:46 ч. UTC

Печалби

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11.03.2026 г., 21:45 ч. UTC

Печалби

Liontown Resources Says FY26 Guidance Unchanged

11.03.2026 г., 21:45 ч. UTC

Печалби

Liontown Resources 1H Unit Operating Costs A$985/Ton

11.03.2026 г., 21:44 ч. UTC

Печалби

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11.03.2026 г., 21:43 ч. UTC

Печалби

Liontown Resources 1H Revenue A$207.5 Million

11.03.2026 г., 21:43 ч. UTC

Печалби

Liontown Resources 1H Net Loss A$184 Million

11.03.2026 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11.03.2026 г., 21:10 ч. UTC

Печалби

Vista Gold FY25 Loss $7.5M >VGZ

11.03.2026 г., 21:10 ч. UTC

Печалби

Vista Gold FY25 Loss/Shr 6c >VGZ

11.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

11.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

11.03.2026 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11.03.2026 г., 20:26 ч. UTC

Печалби

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11.03.2026 г., 20:19 ч. UTC

Значими събития в новините

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11.03.2026 г., 20:15 ч. UTC

Печалби

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11.03.2026 г., 20:12 ч. UTC

Значими събития в новините

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11.03.2026 г., 19:31 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11.03.2026 г., 19:01 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11.03.2026 г., 18:59 ч. UTC

Придобивния, сливания и поглъщания

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11.03.2026 г., 18:43 ч. UTC

Значими събития в новините

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

89.46% нагоре

12-месечна прогноза

Среден 36.13 USD 89.46%

Висок 47 USD

Нисък 21.8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

147 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.